Loading…
Loading…
BICTF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BICTF and 80,000+ other tickers.
See exactly how BICTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BICTF and 80,000+ other tickers.
Biocure Technology Inc., along with its subsidiary, is dedicated to the development and market introduction of biopharmaceutical technologies, particularly those leveraging recombinant proteins and ranibizumab. The company's therapeutic pipeline features Interferons-ß, which are being advanced for the treatment of multiple sclerosis. They are also developing Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related ocular condition known as macular edema. Furthermore, Biocure is progressing Filgrastim, a treatment for neutropenia—a deficiency of white…
Vancouver, B.C. – TheNewswire - May 8, 2026 ‐ Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the “ Company” or “Biocure”) announces the adoption of semi-annual financial reporting. This news release is being filed pursuant to Coordinated Blanket Order 51 – 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (“ CBO 51-933 ”). CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework. Biocure's fiscal year ends on December 31. Under the provisions of CBO 51-933, Biocure will be exempt from the requirements to file its three-month interim financial statements and associated management's discussion and analysis (“ MD&A ”) as it meets the eligibility criteria under CBO 51-933, which include being a venture issuer with annual revenues of less than $10 million and maintaining a clean 12-month continuous disclosure record. Accordingly, Biocure will not be filing its interim financial statements for the three-month period ending March 31, 2026 and associated MD&A.
Toronto, Ontario--(Newsfile Corp. - le 23 octobre/October 2024) - Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every nine (9) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 10,444,504 common shares.
TÜBINGEN, Germany and MUNICH, Germany, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atriva Therapeutics GmbH (“Atriva”) is pleased to disclose the signing of an exclusive letter agreement, dated September 14, 2023, with Biocure Technology Inc. (“CURE”) (CSE: CURE), based in Vancouver, Canada. This agreement marks a significant step forward in Atriva's commitment to combating severe RNA virus infections through innovative host-cell-targeting therapies.
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. ("Atriva") whereby the Company will acquire all of the issued and outstanding securities of Atriva (the "Transaction").
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2021) - BioCure Technology Inc., (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) is pleased to announce that Björn Cochlovius, Ph.D, Assoc.Prof., has joined BioCure Technology Inc. as President. We are also pleased to announce that Diverse Capital Pte Ltd ("Diverse Capital") has been appointed as a Capital Markets Advisor.Dr. Cochlovius brings leadership experience in multiple Management and Board positions. He has experience in science, development, fundraising, partnerships, exit...